Small Biotech Clinical Trial Application (CTA) & Investigational New Drug (IND) Submission Success with Integrated Project Management
Find out how Certara helped a small biotech achieve on-time IND and CTA submissions with…
Certara2025 年 8 月 18 日
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
Certara2025 年 8 月 13 日
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial
Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…
Certara2025 年 8 月 13 日
Certara Reports Second Quarter 2025 Financial Results
RADNOR, PA— 2025 年 8 月 6 日-- Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development,…
Certara2025 年 8 月 6 日
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
Certara2025 年 8 月 6 日
Machine Learning (ML) in healthcare
Learn about 3 distinct examples of machine learning (ML) in healthcare that utilize different techniques…
Certara2025 年 8 月 1 日
